Economiic Home Method Watch Market RSI Search

I-Mab IMAB

Sector:

Healthcare

Industry:

Biotechnology

Description:

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
I-Mab website

Recent Quarter:

2024-11-14

Upcoming Quarter:

2025-03-13

Annual Reports

Date2024-04-30
Revenue 27,644,000
Net Income -1,465,694,000
EPS -17.62
Basic Shares 83,192,989
Diluted Shares 83,227,761
Report Link
Date2023-05-01
Revenue -221,563,000
Net Income -2,507,317,000
EPS -30.39
Basic Shares 82,516,215
Diluted Shares 82,516,214
Report Link
Date2022-04-29
Revenue 88,026,000
Net Income -2,331,541,000
EPS -30.7
Basic Shares 75,933,596
Diluted Shares 75,959,589
Report Link
Date2021-04-28
Revenue 1,542,668,000
Net Income 470,915,000
EPS 8.07
Basic Shares 68,248,560
Diluted Shares 68,361,588
Report Link
Date2020-04-29
Revenue 30,000,000
Net Income -1,485,001,000
EPS -462.74
Basic Shares 3,209,168
Diluted Shares 3,209,230
Report Link
Date2018-12-31
Revenue 53,781,000
Net Income -402,833,000
EPS -141.91
Basic Shares 2,838,651
Diluted Shares 2,838,736
Report Link
Date2017-12-31
Revenue 11,556,000
Net Income -298,240,000
EPS -119.45
Basic Shares 2,496,813
Diluted Shares 2,496,813
Report Link

Annual Ratios

Date2023-12-31
PE -0.77
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.95
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -9.80
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE 44.59
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -0.19
Dividend Yield 1.89
Payout Ratio: -0.356%
Date2018-12-31
PE -0.61
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2017-12-31
PE -0.68
Dividend Yield 0.00
Payout Ratio: 0.000%

Quarterly Reports

Date2024-09-30
Revenue 0
Net Income -20,491,000
EPS -0.25
Basic Shares 81,495,843
Diluted Shares 81,495,843
Report Link
Date2024-06-30
Revenue 0
Net Income 25,126,000
EPS 0.0897
Basic Shares 280,154,673
Diluted Shares 80,931,994
Report Link
Date2024-03-31
Revenue 0
Net Income 20,841,973
EPS 0.25
Basic Shares 82,062,492
Diluted Shares 80,870,270
Report Link
Date2024-04-30
Revenue 3,994,500
Net Income -346,449,000
EPS -4.16
Basic Shares 83,214,058
Diluted Shares 83,287,636
Report Link
Date2023-09-30
Revenue 3,994,500
Net Income -346,449,000
EPS -4.16
Basic Shares 83,214,058
Diluted Shares 83,287,636
Report Link
Date2023-06-30
Revenue 9,827,500
Net Income -386,398,000
EPS -4.65
Basic Shares 83,167,886
Diluted Shares 83,167,886
Report Link
Date2023-03-31
Revenue 9,827,500
Net Income -386,398,000
EPS -4.65
Basic Shares 83,167,886
Diluted Shares 83,167,886
Report Link
Date2023-05-01
Revenue -136,710,500
Net Income -730,230,000
EPS -8.81
Basic Shares 82,874,451
Diluted Shares 82,874,447
Report Link
Date2022-09-30
Revenue -136,710,500
Net Income -730,230,000
EPS -8.81
Basic Shares 82,874,451
Diluted Shares 82,874,447
Report Link
Date2022-11-10
Revenue 25,929,000
Net Income -523,428,500
EPS -6.37
Basic Shares 82,111,905
Diluted Shares 82,111,893
Report Link
Date2022-03-29
Revenue 25,929,000
Net Income -523,428,500
EPS -6.37
Basic Shares 82,111,905
Diluted Shares 82,111,893
Report Link
Date2021-11-12
Revenue 35,125,500
Net Income -627,530,000
EPS -8
Basic Shares 78,466,153
Diluted Shares 78,516,052
Report Link
Date2021-11-12
Revenue 35,125,500
Net Income -627,530,000
EPS -8
Basic Shares 78,466,153
Diluted Shares 78,516,052
Report Link
Date2021-06-30
Revenue 8,887,500
Net Income -538,240,500
EPS -7.33
Basic Shares 73,403,131
Diluted Shares 73,403,126
Report Link
Date2021-03-31
Revenue 8,887,500
Net Income -538,240,500
EPS -7.33
Basic Shares 73,403,131
Diluted Shares 73,403,126
Report Link
Date2021-04-28
Revenue 1,542,668,000
Net Income 1,041,550,000
EPS 14.71
Basic Shares 70,825,846
Diluted Shares 70,882,357
Report Link
Date2021-02-05
Revenue 0
Net Income 12,218,000
EPS 0.21
Basic Shares 61,177,177
Diluted Shares 59,410,787
Report Link
Date2020-07-15
Revenue 0
Net Income -291,426,500
EPS -5.5
Basic Shares 52,963,476
Diluted Shares 52,963,472
Report Link
Date2020-03-31
Revenue 0
Net Income -291,426,500
EPS -5.5
Basic Shares 52,963,476
Diluted Shares 52,963,472
Report Link
Date2020-04-29
Revenue 0
Net Income -381,621,000
EPS -110.09
Basic Shares 3,466,330
Diluted Shares 3,466,372
Report Link
Date2019-09-30
Revenue 15,000,000
Net Income -246,043,000
EPS -78.78
Basic Shares 3,123,364
Diluted Shares 3,123,516
Report Link
Date2019-06-30
Revenue 7,500,000
Net Income -428,668,500
EPS -137.24
Basic Shares 3,123,472
Diluted Shares 3,123,516
Report Link
Date2019-03-31
Revenue 7,500,000
Net Income -428,668,500
EPS -137.24
Basic Shares 3,123,472
Diluted Shares 3,123,516
Report Link
Date2018-12-31
Revenue 10,390,000
Net Income -123,465,000
EPS -41.02
Basic Shares 3,010,165
Diluted Shares 3,010,165
Report Link
Date2018-09-30
Revenue 22,014,000
Net Income -112,648,000
EPS -40.5
Basic Shares 2,781,226
Diluted Shares 2,781,593
Report Link
Date2018-06-30
Revenue 10,688,500
Net Income -83,360,000
EPS -29.97
Basic Shares 2,781,541
Diluted Shares 2,781,593
Report Link
Date2018-03-31
Revenue 10,688,500
Net Income -83,360,000
EPS -29.97
Basic Shares 2,781,540
Diluted Shares 2,781,593
Report Link

Quarterly Ratios

Date2024-09-30
PE -1.23
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2024-06-30
PE 32.81
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2024-03-31
PE 12.88
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-12-31
PE -0.81
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-09-30
PE -0.58
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-06-30
PE -1.17
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2023-03-31
PE -1.28
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-12-31
PE -0.82
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-09-30
PE -0.81
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-06-30
PE -2.97
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2022-03-31
PE -4.04
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-12-31
PE -9.41
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-09-30
PE -14.61
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-06-30
PE -18.48
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2021-03-31
PE -10.83
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-12-31
PE 5.23
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-09-30
PE 399.78
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-06-30
PE -9.61
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2020-03-31
PE -4.18
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-12-31
PE -0.20
Dividend Yield 1.75
Payout Ratio: -1.384%
Date2019-09-30
PE -0.28
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-06-30
PE -0.16
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2019-03-31
PE -0.15
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2018-12-31
PE -0.52
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2018-09-30
PE -0.53
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2018-06-30
PE -0.69
Dividend Yield 0.00
Payout Ratio: 0.000%
Date2018-03-31
PE -0.65
Dividend Yield 0.00
Payout Ratio: 0.000%

RSI:

30.64

Price:

$0.98

Market Cap:

75,482,836

EPS TTM:

-4.07

PE Ratio:

-1.80

PEPSG:

21.3333

Fwd PE:

-38.44

Volume:

381,498

2 Year Price Change

0.263

Index 2 Year Price Change

1.497

5 Year Price Change

No Price 5 Years Ago

Index 5 Year Price Change

1.905
PESPG: Growth Rate of EPS projected to next quarter and 6 months trailing. Lower is better to help calculate nexts quarters PE Ratio today. Diluted shares effects the EPS reported and makes calculation show as extremely poor expected growth.

Revenue

Net Income

EPS

Shares

News

Press Releases

Notable Earnings

Please select an option: